Muallem Classification of Radical Hysterectomy

Background and Rationale

Why a New Classification Was Needed

1. Lateral-only orientation: Both Piver and Querleu-Morrow (Q-M) classifications define radicality based on lateral extent alone. This fails to reflect the true 3-dimensional anatomy of the parametrium (which has ventral, lateral, and dorsal components) and does not capture 3D tumor spread.
2. Arbitrary "halfway" resection: The Q-M Type B and Piver Class II define parametrial transection at "midway" between the cervix and the pelvic wall. This does not correlate with actual tumor spread patterns. Continuous parametrial invasion is rare; tumor spreads mainly via emboli and lymph node involvement, and the distal lateral parametrial lymph nodes are neglected in halfway resection.
3. Not tailored to FIGO staging: Prior classifications do not directly map onto the 2018 FIGO staging for cervical cancer or allow individualized (tailored) surgical radicality based on tumor size, location, and vaginal vault infiltration.
4. Neglect of paracolpium and vaginal vault: Piver and Q-M systems do not adequately describe parametrial anatomy in relation to the paracolpium (paravaginal tissue) as a distinct surgical entity.
5. Pelvic exenteration excluded: Muallem deliberately excludes pelvic exenteration (Piver Class V / Q-M Type D) because it is rarely indicated and is better considered separately.

The Four Types of Muallem Classification

Type I - Limited Radical Hysterectomy

• Equivalent to: Q-M Class A (extrafascial hysterectomy)
• Resection line: Proximal aspects of ventral, lateral, and dorsal parametrium
• Vaginal cuff: Minimal vaginal vault (no vaginal vault needed)
• Indication: FIGO Stage IA microscopic cervical cancer with no LVSI (lymphovascular space invasion)
• Rationale: Microscopic disease confined to cervix with no LVSI has near-zero parametrial involvement; maximal radicality is not warranted and increases morbidity unnecessarily

Type II - Typical Radical Hysterectomy

• Equivalent to: Q-M Class C1/C (nerve-sparing)
• Resection line: Distal aspects of ventral, lateral, and dorsal parametrium - but no resection of paracolpium
• Vaginal cuff: Standard
• Pelvic autonomic nerves: Preserved (nerve-sparing)
• Indication: FIGO Stage IA2 and IB1 (tumor <2 cm), IB2 (2-4 cm) without deep stromal invasion or vaginal involvement
• Rationale: Complete parametrial resection to the pelvic wall without paravaginal resection; nerve-sparing is possible and reduces bladder dysfunction

Type III - Typical Radical Hysterectomy with Extended Vaginal Cuff Resection

• Resection line: Distal aspects of ventral, lateral, and dorsal parametrium AND proximal aspects of ventral, lateral, and dorsal paracolpium
• Vaginal cuff: Extended resection of upper vagina
• Indication: FIGO Stage IB2 with deep stromal invasion, IB3 with dorsal localization
• Rationale: Tumors with deep invasion or posterior localization require resection into the proximal paracolpium to achieve oncologically adequate margins

Type IV - Radical Hysterectomy with Radical Upper Colpectomy

• Resection line: Distal aspects of ventral, lateral, and dorsal parametrium AND distal aspects of ventral, lateral, and dorsal paracolpium
• Inferior hypogastric plexus: Ipsilateral resection is mandatory if direct infiltration of paracolpium or endopelvic fascia is present
• Indication: FIGO Stage IB3 with ventral localization or deep stromal invasion, Stage IIA, and selected Stage IIB cases
• Rationale: Maximal radicality for larger or anteriorly located tumors with vaginal involvement; sacrifice of autonomic nerves is acceptable given oncologic necessity

Comparison with Other Classifications

Complications of Radical Hysterectomy

Intraoperative Complications

• Hemorrhage - from uterine vessels, internal iliac vessels, or venous plexuses; risk increases with higher radicality (Type IV > Type I)
• Ureteral injury - transection or devascularization during parametrial dissection; more common with non-nerve-sparing approaches
• Bladder injury - during dissection of vesicouterine space/vesicovaginal ligament
• Bowel injury - less common; risk increases with adhesions or extended resection
• Vascular injury - to internal iliac, obturator, or external iliac vessels during lymphadenectomy

Early Postoperative Complications

• Urinary tract complications (most common):
  • Urinary retention / neurogenic bladder - from disruption of inferior hypogastric plexus (parasympathetic supply to detrusor)
  • Ureterovaginal fistula
  • Vesicovaginal fistula
  • Hydronephrosis/ureteral stricture from devascularization
• Lymphocele - after pelvic lymphadenectomy; can become infected or compress the ureter
• Deep vein thrombosis / pulmonary embolism - significant risk given pelvic surgery and cancer-associated hypercoagulability
• Wound infection / dehiscence (open approach)
• Ileus or bowel obstruction
• Lymphedema of lower limbs - after pelvic/para-aortic lymphadenectomy

Late Complications

• Bladder dysfunction (most clinically significant long-term morbidity):
  • Detrusor hypotonia / acontractile bladder requiring intermittent self-catheterization
  • Stress urinary incontinence (sphincteric damage)
  • Overactive bladder
  • Voiding difficulty
  • This is directly related to damage to the inferior hypogastric plexus and is the main justification for nerve-sparing techniques (Q-M C1 and Muallem Type II)
• Sexual dysfunction: dyspareunia, reduced vaginal length, decreased lubrication from vaginal cuff shortening
• Bowel dysfunction: constipation, rectal hypomotility from sympathetic nerve damage
• Ureteral stricture / hydronephrosis (late)
• Lymphedema (chronic)
• Ovarian failure if oophorectomy performed (though ovaries can be conserved in cervical cancer)

Risk Factors That Increase Complication Rate

• More advanced stage requiring higher radicality (Type III-IV > Type I-II)
• Obesity, diabetes
• Postoperative surgical infection
• Adjuvant radiation (combined modality increases fistula and bowel complication risk significantly)
• Minimally invasive approach in tumors >2 cm (LACC trial showed worse oncologic outcomes with MIS for tumors ≥2 cm) - Berek & Novak's Gynecology

Key Takeaway on Muallem's Contribution